Former Chief Executive Officer and Director · ZEVRA THERAPEUTICS, INC. (ZVRA)

Richard Pascoe

A named executive officer of ZEVRA THERAPEUTICS in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,122,558

Salary $273,576Stock awards $0

FY2022: $1,360,976

1st of 6 named executive officers at Zevra Therapeutics by FY2023 total.

6 named officers on file for ZEVRA THERAPEUTICS, FY2023

Richard Pascoe’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ZEVRA THERAPEUTICS’s whole pay program stands against its peers

  • ZEVRA THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZVRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2024 (DEF 14A).

Free

Get Richard Pascoe’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Richard Pascoe compensation by year

ZEVRA THERAPEUTICS Summary Compensation Table · all 3 fiscal years held
In US dollars, as ZEVRA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$119,814$422,917$273,576
Bonus$0$0$0
Stock awards$0$0$0
Option awards$540,401$722,921$3,469,457
Non-equity incentive$50,000$202,938$0
Pension and deferred compensation$0$0$0
All other$2,267$12,200$379,525
Total$712,482$1,360,976$4,122,558

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ZEVRA THERAPEUTICS, INC. DEF 14A filed April 3, 2024, accession 0001437749-24-010874, and prior-year filings.

How this page was built: the ZEVRA THERAPEUTICS, INC. filed document, accession 0001437749-24-010874. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2024.

$712K
$1.4M
$4.1M
FY21
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

ZEVRA THERAPEUTICS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Richard Pascoe · this pageFormer Chief Executive Officer and Director$4,122,558
Travis MickleFormer President, Chief Executive Officer and Director$3,593,438
Neil McFarlanePresident, Chief Executive Officer and Director$3,445,231
R. LaDuane CliftonChief Financial Officer, Secretary and Treasurer$2,263,257
Joshua SchaferChief Commercial Officer and Executive Vice President, Business Development$1,814,465
Christal MickleFormer Interim Chief Executive Officer$1,669,956

The full ZEVRA THERAPEUTICS compensation record

free company brief

This page is one person within ZEVRA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ZEVRA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Richard Pascoe's compensation dossier · One-time report. No refunds.